Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT

Journal of International Medical Research

Volumn 35, Issue 4, 2007, Pages 547-553

  Akcali, Cenk ^a,c   Zincirkeser, S ^a   Erbagcy Z ^a   Akcali, A ^a   Halac, M ^b   Durak, G ^a   Sager, S ^b   Sahin, E ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Universite Bul23 Nisan Mah   (Turkey)

Author keywords

Computed tomography (CT); Flourodeoxyglucose (FDG); Melanoma; Metastases; Positron Emission Tomography (PET)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER CYST; MALE; MELANOMA; METASTASIS; POSITRON EMISSION TOMOGRAPHY; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; SKIN CANCER; WHOLE BODY TOMOGRAPHY;

EID: 34547905766     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500415     Document Type: Article

References (37)

1. Langley RGB, Barnhill RL, Mihm MC, et al: Neoplasms: cutaneous melanoma. In: Fitzpatrick's Dermatology in General Medicine (Freedberg IM, Eisen AZ, Wolff K, et al, eds) 6th edn. New York: McGraw-Hill, 2003; pp 917-947.
2. Hall HI, Miller DR, Rogers ID, et al: Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999; 40: 35-42.
3. Reintgen D, Cruse CW, Wells K, et al: The orderly progression of melanoma nodal metastases. Ann Surg 1994; 220: 759-767.
4. Meier F, Will S, Ellwanger U, et al: Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147: 62-70.
5. Skobe M, Hamberg LM, Hawighorst T, et al: Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001; 159: 893-903.
6. Leiter U, Meier F, Schittek B, et al: The natural course of cutaneous melanoma. J Surg Oncol 2004; 86: 172-178.
7. King DM: Imaging of metastatic melanoma. Cancer Imaging 2006; 6: 204-208.
8. Miranda EP, Gertner M, Wall J, et al: Routine imaging of asymptomatic melanoma patients with metastases to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004; 139: 831-837.
9. Swetter S, Carroll L, Johnson D, et al: Positron emission tomography (PET) is superior to computerized tomography (CT) for metastatic staging in melanoma patients. Clin Positron Imaging 2000; 3: 154.
10. Gulec SA, Faties MB, Lee CC, et al: The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision. Clin Nucl Med 2003: 28: 961-965.
11. Jadvar H, Johnson DL, Segall GM: The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med 2000; 25: 48-51.
12. Schwimmer J, Essner R, Patel A, et al: A review of the literature for wholebody FDG PET in the management of patients with melanoma. Q J Nucl Med 2000; 44: 153-167.
13. Schöder H, Larson SM, Yeung HW: PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004; 45(Suppl 1): 72S-81S.
14. Prichard RS, Hill AD, Skehan SJ, et al: Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002; 89: 389-396.
15. Holder WD Jr, White RL Jr, Zuger JH, et al: Effectiveness of positron emission tomography for detection of melanoma metastases. Ann Surg 1998; 225: 764-771.
16. 18F-fluorodeoxyglucose positron emission tomography. Cancer 1998; 82: 1664-1671.
17. Tyler DS, Onaitis M, Kherani A, et al: Positron emission tomography screening in malignant melanoma. Cancer 2000; 89: 1019-1025.
18. Stas M, Stroobants S, Dupont P, et al: 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002; 12: 479-490.
19. Beyer T, Townsend DW, Brun T, et al: A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-1379.
20. Townsend DW, Carney JP, Yap JT, et al: PET/CT today and tomorrow. J Nucl Med 2004; 45(Suppl 1): 4-14.
21. Kumar R, Mavi A, Bural G, et al: Fluorodeoxyglucose-PET in the management of malignant melanoma. Radiol Clin North Am 2005; 43: 23-33.
22. 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006; 24: 1178-1187.
23. 18F-FDG PET in melanoma patients. Cancer 2001; 91: 1530-1542.
24. Macapinlac HA: FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J 2004; 10: 262-270.
25. Freudenberg LS, Schueler AO, Beyer T, et al: Whole-body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma. Surv Ophthalmol 2004; 49: 537-540.
26. Finger PT, Kurli M, Reddy S, et al: Whole-body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 2005; 89: 1270-1274.
27. 18FFDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004; 45: 1804-1810.
28. Brand CU, Ellwanger U, Stroebel W, et al: Prolonged survival of 2 years or longer for patients with disseminated melanoma: an analysis of related prognostic factors. Cancer 1997; 70: 2345-2353.
29. Meyer T, Merkel S, Goehl J, et al: Surgical therapy for distant metastases of malignant melanoma. Cancer 2000; 89: 1983-1991.
30. Stas M, Stroobants S, Dupont P, et al: 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002; 12: 479-490.
31. Swetter SM, Carroll LA, Johnson DL, et al: Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002; 9: 646-653.
32. 18F]fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician's perspective. Mol Imaging Biol 2002; 4: 185-190.
33. Jadvar H, Johnson DL, Segall GM: The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med 2000; 25: 48-51.
34. Larcos G, Maisey MN: FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 1996; 17: 197-198.
35. Patz EF Jr, Lowe VJ, Hoffman JM, et al: Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188: 487-490.
36. Avril N, Dose J, Janicke F, et al: Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14: 1848-1857.
37. Lowe VJ, Fletcher JW, Gobar L, et al: Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16: 1075-1084.